medigraphic.com
Revista Médica Sinergia

2020, Número 05

<< Anterior Siguiente >>

Revista Médica Sinergia 2020; 5 (05)


Síndrome opsoclonus – mioclonus

Delgado CLG, Benavides VJD, Marín RGJ

Idioma: Español
Referencias bibliográficas: 19
Paginas: 420-420
Archivo PDF: 155.63 Kb.


RESUMEN

El síndrome opsoclonus-mioclonus es una condición rara, asociada con una etiología de carácter autoinmune, tanto paraneoplásica, parainfecciosa o idiopática. Estos pacientes se presentan con ataxia del tronco y extremidades, con caídas, opsoclonus, mioclonías, y se puede acompañar de diversos grados de encefalopatía, signos cerebelosos y alteraciones del sueño. En el caso de la población pediátrica, se debe evaluar por neuroblastoma; y en adultos con encefalopatía asociada se debe realizar una evaluación exhaustiva para detectar malignidad oculta. Mientras que los síntomas neurológicos agudos pueden controlarse mediante inmunoterapia, y se ha visto respuesta parcial a tratamiento antitumoral, el resultado a largo plazo se caracteriza por la presencia de déficit neuropsicológico.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Oh S, Kim J, Dieterich M. Update on opsoclonus–myoclonus syndrome in adults. Journal of Neurology. 2019; 266(6): 1541-1548. https://doi.org/10.1007/s00415-018-9138-7

  2. Chekroud A, Anand G, Yong J, Pike M, Bridge H. Altered functional brain connectivity in children and young people with opsoclonus-myoclonus syndrome. Developmental Medicine & Child Neurology. 2016; 59(1): 98-104. https://doi.org/10.1111/dmcn.13262

  3. Pranzatelli M, Tate E, McGee N. Demographic, Clinical, and Immunologic Features of 389 Children with Opsoclonus-Myoclonus Syndrome: A Cross-sectional Study. Frontiers in Neurology. 2017; 8. https://doi.org/10.3389/fneur.2017.00468

  4. Stewart K, Lee J, Stuart G. Paraneoplastic opsoclonus-myoclonus syndrome as a presentation of high grade serous ovarian cancer. Gynecologic Oncology Reports. 2019; 30: 100511. https://doi.org/10.1016/j.gore.2019.100511

  5. Radu R, Terecoasă E, Ene A, Băjenaru O, Tiu C. Opsoclonus-Myoclonus Syndrome Associated With West-Nile Virus Infection: Case Report and Review of the Literature. Frontiers in Neurology. 2018; 9. https://doi.org/10.3389/fneur.2018.00864

  6. Pranzatelli MR, Tate ED, McGee NR. Multifactorial analysis of opsoclonus-myoclonus syndrome etiology (“Tumor” vs. “No tumor”) in a cohort of 356 US children. Pediatric Blood Cancer. 2018; 65(8): 1-12. https://doi.org/10.1002/pbc.27097

  7. Blaes F, Dharmalingam B, Childhood opsoclonus-myoclonus syndrome: diagnosis and treatment. Expert review of neurotherapeutics. 2016; 16(6): 641-8. https://doi.org/ 10.1080/14737175.2016.1176914

  8. Huddar A, Bindu PS, Nagappa M, Bharath RD2, Sinha S, Mathuranath PS, Taly AB. Pediatric opsoclonusmyoclonus- ataxia syndrome: Experience from a tertiary care university hospital. 2018; 66(5): 1332-133. https://doi.org/10.4103/0028-3886.241404

  9. Lizarraga KJ, Heros DO, Adams D, Lang AE, Kanner M . Opsoclonus-myoclonus-encephalopathy induced by cefepime. Journal of the neurological sciences. 2019; 396: 33-35. http://doi.org/10.1016/j.jns.2018.10.028

  10. Necpál J , Skorvanek M.Opsoclonus-myoclonus ataxia syndrome secondary to venlafaxine intoxication. Journal of the neurological sciences. 2017; 372: 19-20.

  11. Gorman MP. Update on diagnosis, treatment, and prognosis in opsoclonus–myoclonus–ataxia syndrome. Current opinion in pediatrics. 2010; 22(6): 745-50. https://doi.org/10.1097/MOP.0b013e32833fde3f

  12. Rodríguez DA, Gelvez JD. Síndrome opsoclonus mioclonus paraneoplásico en pediatría: reporte de caso y revisión de la literatura. Acta Neurol Colomb. 2015; 31(2):209-213. https://doi.org/10.22379/2422402230

  13. Galstyan A, Wilbur C, Selby K, Hukin J. Opsoclonus-myoclonus syndrome: a new era of improved prognosis? Pediatric Neurology. 2017; 72:65-69. https://doi.org/10.1016/j.pediatrneurol.2017.03.011

  14. Armangué T, Sabater L, Torres-Vega E, et al. Clinical and Immunological Features of Opsoclonus- Myoclonus Syndrome in the Era of Neuronal Cell Surface Antibodies. JAMA Neurol. 2016; 73: 417. https://doi.org/10.1001/jamaneurol.2015.4607

  15. Hasegawa S, Matsushige T, Kajimoto M, et al. A nation wide survey of opsoclonus-myoclonus syndrome in Japanese children. Brain Dev. 2015; 37: 656. https://doi.org/10.1016/j.braindev.2014.10.010

  16. Schleiermacher G, Hero B. Update on Pediatric Opsoclonus Myoclonus Syndrome. Neuropediatrics. 2013; 44(06): 324-329. https://doi.org/10.1055/s-0033-1358604

  17. Wilbur C, Yea C, Licht C, Irwin M, Yeh E. An upfront immunomodulatory therapy protocol for pediatric opsoclonus􀇦myoclonus syndrome. Pediatric Blood & Cancer. 2019; 66(8). https://doi.org/10.1002/pbc.27776

  18. Mitchell W, Wooten A, O’Neil S, Rodriguez J, Cruz R, Wittern R. Effect of Increased Immunosuppression on Developmental Outcome of Opsoclonus Myoclonus Syndrome (OMS). Journal of Child Neurology. 2014; 30(8): 976-982. https://doi.org/10.1177/0883073814549581

  19. Dulac O, Lassonde M, Sarnat H. Pediatric Neurology, Part II. 3rd ed. Burlington: Elsevier Science; 2013.




2020     |     www.medigraphic.com